This new agent represents a new approach to the treatment of erosive inflammatory arthritis. On the surface, using a drug with no effect on articular inflammation may not sound viable. However, it is compelling to contemplate combination regimens with denosumab that may result in control of articular signs and symptoms with concomitant suppression of erosions with little risk of additional toxic side effects. It is interesting to note that joint space narrowing was not suppressed by denosumab, suggesting that the mechanisms of cartilage destruction and erosions are distinct in RA. The efficacy of denosumab to treat post-menopausal osteoporosis is a potential added benefit.
A Small Favor
More than 15 years ago the Arthritis Center launched this website with the mission to bring current and accurate disease education to health care professionals and patients alike. Content on our site is generated directly by our team members. Unlike many health education websites we do not accept advertising, paid guests posts or charge for access to our site.
That’s where you come in. Your support will allow us to continue to deliver this valuable information to over 1 million visitors each year.Contribute TodayMore Ways to Give